公开(公告)号：US12104188B2

公开(公告)日：2024-10-01

申请号：US17716253

申请日：2022-04-08

申请人： Allogene Therapeutics, Inc.

发明人： Meritxell Galindo Casas ,  Thomas John Van Blarcom

IPC分类号： C12N9/64 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/48 ,  A61K38/52 ,  C12N5/0783 ,  C12N9/90 ,  C12N11/18

CPC分类号： C12N9/6472 ,  A61K31/7088 ,  A61K35/17 ,  A61K38/4873 ,  A61K38/52 ,  C12N5/0636 ,  C12N9/90 ,  C12N11/18 ,  C12Y304/22062 ,  C12Y502/01008 ,  C07K2319/50 ,  C07K2319/70 ,  C12N2501/734 ,  C12N2510/00 ,  C12N2740/16043

摘要： Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides. The disclosure further provides polynucleotides encoding these proteins, engineered host cells containing these polynucleotides and proteins, including host cells that co-express a chimeric antigen receptor, and methods of making and using the same.

公开(公告)号：US20240285735A1

公开(公告)日：2024-08-29

申请号：US18657124

申请日：2024-05-07

申请人： MEDIWOUND LTD.

发明人： Evgenia LOZINSKY ,  Dafna GEBLINGER ,  Deborah Hanah BARTFELD ,  Eilon ASCULAI

IPC分类号： A61K38/48 ,  A61K9/06 ,  A61K47/36 ,  A61L26/00 ,  A61P17/02

CPC分类号： A61K38/4873 ,  A61K9/06 ,  A61K47/36 ,  A61L26/0052 ,  A61L26/008 ,  A61P17/02 ,  A61L2300/412

摘要： The present invention relates to compositions and methods of wound debridement and stimulation of granulation tissue formation, thereby preparing the wound bed to facilitate and promote the process of wound healing. In particular, the present invention relates to methods of debridement of chronic wounds by topically applying to a wound site or bed a composition containing a proteolytic enzyme mixture obtained from bromelain and a water-soluble gelling agent, the composition being applied to the wound site or bed up to ten times over a period of up to four weeks, resulting in a clean wound bed covered with granulation tissue prepared towards wound healing.

公开(公告)号：US20240271115A1

公开(公告)日：2024-08-15

申请号：US18570529

申请日：2022-06-14

申请人： The University of North Carolina at Chapel Hill

发明人： Haiyan Fu ,  Tierra Bobo ,  Preston Samowitz ,  Brian Kuhlman ,  David Forrest Thieker

IPC分类号： C12N9/52 ,  A61K38/00 ,  A61K38/48 ,  A61K48/00

CPC分类号： C12N9/52 ,  A61K38/4873 ,  A61K48/0083 ,  C12Y304/2201 ,  A61K38/00

摘要： This invention relates to methods and compositions for inhibiting or depleting antibodies, e.g., total IgG including neutralizing antibodies. In particular, the invention relates to methods of inhibiting or depleting antibodies against a heterologous agent when the heterologous agent is administered to a subject, comprising administering to the subject an effective amount of recombinant or modified Streptococcus pyogenes IgG degrading enzyme (IdeS) prepared from codon-optimized nucleic acids and/or modified nucleic acids, thereby inhibiting or depleting antibodies and inhibiting neutralization of the heterologous agent, e.g., to improve viral vector-mediated gene therapy.

公开(公告)号：US20240226250A9

公开(公告)日：2024-07-11

申请号：US18547979

申请日：2022-02-24

申请人： CHONGQING CLARUVIS PHARMACEUTICAL CO., LTD.

发明人： Yan ZHANG

IPC分类号： A61K38/48 ,  A61K8/66 ,  A61Q19/00 ,  C12N9/52

CPC分类号： A61K38/4873 ,  A61K8/66 ,  A61K38/482 ,  A61Q19/00 ,  C12N9/52 ,  C12Y304/22002 ,  C12Y304/24069

摘要： The present invention relates to a modified neurotoxin single-chain polypeptide and a use thereof. The single-chain polypeptide contains a tagged protein, a linker short peptide, etc. The linker short peptide facilitates cleavage of the tagged protein, thereby improving purification of the single-chain polypeptide; in addition, the single-chain polypeptide has neurotoxicity when activated, but the single-chain polypeptide per se is only slightly toxic, such that the production safety is improved and the production process cost is reduced while the yield of the single-chain polypeptide is greatly increased.

公开(公告)号：US20240115671A1

公开(公告)日：2024-04-11

申请号：US18276628

申请日：2022-02-09

申请人： University of Massachusetts ,  Ernest Pharmaceuticals, Inc.

发明人： Neil S. Forbes ,  Vishnu Raman ,  Nele Van Dessel ,  Jeanne A. Hardy

IPC分类号： A61K38/48 ,  A61K35/74 ,  A61K38/46 ,  C12N1/20 ,  C12N1/36 ,  C12N9/16 ,  C12N9/64 ,  C12N15/74

CPC分类号： A61K38/4873 ,  A61K35/74 ,  A61K38/465 ,  C12N1/20 ,  C12N1/36 ,  C12N9/16 ,  C12N9/6472 ,  C12N15/74 ,  C12Y301/04 ,  C12Y304/22056 ,  C12N2800/101 ,  C12N2830/002

摘要： Provided herein is a bacterial delivery platform that harnesses mechanisms unique to Salmonella to intracellularly deliver protein-based drugs.

公开(公告)号：US20240091324A1

公开(公告)日：2024-03-21

申请号：US17768038

申请日：2020-10-09

申请人： Anatara Lifesciences Ltd

发明人： Tracey BROWN

IPC分类号： A61K38/48 ,  A61K9/28 ,  A61K31/045 ,  A61K31/198 ,  A61K31/593 ,  A61P1/00 ,  A61P29/00

CPC分类号： A61K38/4873 ,  A61K9/2846 ,  A61K31/045 ,  A61K31/198 ,  A61K31/593 ,  A61P1/00 ,  A61P29/00 ,  C12Y304/22032 ,  C12Y304/22033

摘要： The present invention relates to a composition for improving gastrointestinal health comprising bromelain enzyme, short-chain fatty acids, specified amino acids, and vitamin D.

公开(公告)号：US20230355726A1

公开(公告)日：2023-11-09

申请号：US17847753

申请日：2022-06-23

申请人： Advanced Enzyme Technologies Ltd.

发明人： Vasant Laxminarayan RATHI ,  Neha SHAH

IPC分类号： A61K38/54 ,  A61K38/48

CPC分类号： A61K38/54 ,  A61K38/482 ,  A61K38/4886 ,  A61K38/4873 ,  C12Y304/2404 ,  C12Y304/21062 ,  C12Y304/22033

摘要： An oral fibrinolytic composition comprising the enzymes serrapeptase and nattokinase. The composition treats and/or may prevent fibrosis conditions and their related symptoms in animals, including humans. This composition may further comprise of one or more enzymes, bioflavonoids, vitamins, coenzymes, minerals, probiotics, prebiotics, herbs, excipients and/or combinations thereof. The composition may improve lung capacity, oxygen saturation, vigor, and/or lung function. It may further alleviate dyspnea, limitations and fear caused by dyspnea, cough, phlegm, fatigue, body pain, chest discomfort, anxiety, depression, loss of appetite, and/or respiratory disorders. The composition of serrapeptase and nattokinase and/or one or more additional component may improve immune health, sleep, health-related quality of life (HRQoL), social well-being, health status, mental health and/or exercise capacity. The present disclosure also provides a method for improving or reducing the frequency and severity of fibrosis and related symptoms in a subject having a fibrotic disease.

公开(公告)号：US20230346866A1

公开(公告)日：2023-11-02

申请号：US17912633

申请日：2021-03-19

申请人： NOVEL CONCEPTS MEDICAL LTD

发明人： Rachel ALKALAY

IPC分类号： A61K36/53 ,  A61K36/258 ,  A61K36/324 ,  A61K36/424 ,  A61K36/71 ,  A61K36/738 ,  A61K36/85 ,  A61K38/48 ,  A61P31/14

CPC分类号： A61K36/53 ,  A61K36/258 ,  A61K36/324 ,  A61K36/424 ,  A61K36/71 ,  A61K36/738 ,  A61K36/85 ,  A61K38/4873 ,  A61P31/14

摘要： A method of preventing or treating non-malignant respiratory disease (NMRD) in a subject in need thereof is provided. The method comprising administering to the subject an effective amount of a plant species or genus thereof-derived component selected from the group consisting of a plant part, extract thereof, fraction thereof, active ingredient thereof, synthetic analog thereof, mimetic thereof or combination thereof, wherein the component is capable of ameliorating symptoms of NMRD and wherein the plant species is selected from the group consisting of Nigella sativa, Thymus capitatus, Thymus vulgaris, Origanum syriacum, Thymbra spicata, Satujera thymbra, Sesamum indicum, Rhus coriaria, Gynostemma polyphyllum, Boswellia sacra and Panax ginseng preventing or treating NMRD in the subject.

公开(公告)号：US20230295241A1

公开(公告)日：2023-09-21

申请号：US18167257

申请日：2023-02-10

申请人： TIBA BIOTECH

发明人： Jasdave S CHAHAL ,  Justine S. McPARTLAN

IPC分类号： C07K14/005 ,  C12N9/50 ,  C07K14/715 ,  C12N15/86 ,  A61P35/00 ,  A61K39/12 ,  A61K38/16 ,  A61K38/17 ,  A61K38/48 ,  A61K45/06 ,  C12N7/00

CPC分类号： C07K14/005 ,  C12N9/506 ,  C12Y304/22028 ,  C07K14/7156 ,  C12N15/86 ,  A61P35/00 ,  A61K39/12 ,  A61K38/162 ,  A61K38/1793 ,  A61K38/4873 ,  A61K45/06 ,  C12N7/00 ,  A61K2039/585

摘要： Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.

公开(公告)号：US20230270831A1

公开(公告)日：2023-08-31

申请号：US17934501

申请日：2022-09-22

申请人： Baylor College of Medicine

发明人： Malcolm K. Brenner ,  Jack James

IPC分类号： A61K38/52 ,  A61K35/28 ,  A61K35/545 ,  A61K39/00 ,  C12N5/0783 ,  C12N5/0775 ,  A61K35/17 ,  A61K38/48

CPC分类号： A61K38/52 ,  A61K35/28 ,  A61K35/545 ,  A61K39/001 ,  C12N5/0636 ,  C12N5/0663 ,  A61K35/17 ,  A61K38/4873 ,  C07K2319/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  C12N2501/48 ,  C12N2510/00 ,  C12Y304/22062 ,  C12Y502/01008

摘要： Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.